NEW YORK, Aug. 19 (GenomeWeb News) - CuraGen subsidiary 454 Life Sciences has exclusively licensed sequencing by synthesis and pyrophosphate-based sequencing techniques from Pyrosequencing of Uppsala, Sweden, the companies said today.
Under the agreement, 454 of Branford, Conn., will pay Pyrosequencing at least $4.5 million.
After the fifth year, 454 has an option to maintain the exclusivity of the license at a cost of $500,000 to $1 million per year.
The license provides 454 with the exclusive worldwide rights for five years to use the technology in whole genome analysis - and in making instruments and kits that use the technology - while Pyrosequencing will retain rights for other applications.